Eligibility (mo)	Platinum Regimen	Patient Number	Comparator	Comments on Outcome (mo)
mo = month; OS = overall survival; PFS = progression-free survival.
Platinum sensitive (>6)	Carboplatin + pegylated-liposomal doxorubicin	104	None	PFS median 9; OS median 31[2]
Platinum sensitive (>6)	Carboplatin + epirubicin	190	Carboplatin	Powered for response differences; OS 17 vs. 15 [3]
Platinum sensitive (≥12)	Cisplatin + doxorubicin + cyclophosphamide	97	Paclitaxel	PFS 15.7 vs. 9; OS 34.7 vs. 25.8 [4]
Platinum sensitive (>6)	Carboplatin + gemcitabine	356	Carboplatin	PFS 8.6 vs. 5.8*; OS 18 vs. 17 [5]
Platinum sensitive (>6)	Cisplatin or carboplatin + paclitaxel	802	Single or nontaxane + platinums	PFS 11 vs. 9; OS 24 vs. 19 [6]

References

2. Ferrero JM, Weber B, Geay JF, et al.: Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2): 263-8, 2007.  [PUBMED Abstract]
   
   
3. Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81 (1): 3-9, 2001.  [PUBMED Abstract]
   
   
4. Cantù MG, Buda A, Parma G, et al.: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (5): 1232-7, 2002.  [PUBMED Abstract]
   
   
5. Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699-707, 2006.  [PUBMED Abstract]
   
   
6. Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375): 2099-106, 2003.  [PUBMED Abstract]